Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.55 |
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306576 | 0.86 | MAP2K1 (0.61) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL12729266 | 0.86 | MAP2K1 (0.66) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL4466016 | 0.86 | MAP2K1 (0.61) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL13333283 | 0.86 | MAP2K1 (0.61) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL29443820 | 0.83 | MAP2K1 (0.67) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL3608096 | 0.83 | MAP2K1 (0.67) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL857071 | 0.83 | MAP2K1 (0.58) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL29468201 | 0.83 | MAP2K1 (0.71) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL27708260 | 0.83 | MAP2K1 (0.71) | MAP2K1CCNE1CDK2MTNR1AADORA2A | |
| SCHEMBL985214 | 0.83 | MAP2K1 (0.71) | MAP2K1CCNE1CDK2MTNR1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2021064141-A1 | INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B | TOLREMO THERAPEUTICS AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021064141-A1 | INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B | TOLREMO THERAPEUTICS AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-7585876-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585876-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
| US-6800640-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
| EP-1178045-B1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-0870768-B1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1178045-A1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER INC. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5977131-A | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0870768-A1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | MAP2K1 2689/4885CCNE1 4124/4885CDK2 2765/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP2K1 335/4885CCNE1 982/4885CDK2 44/4885 |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR7 | MAP2K1 2720/4885CCNE1 4392/4885CDK2 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.